[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522693":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":29,"responsibleParty":57,"collaborators":19,"id":60,"slug":19,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":19,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":19,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":19,"overallStatus":49,"whyStopped":19,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"University of Kansas Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ketamine","EXPERIMENTAL","All patients will receive the experimental drug.",[13],"Drug: Ketamine",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Patients will receive 0.2mg\u002Fkg of IV ketamine",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Lindsay Maguire, MD","CONTACT","913-588-3580","lmaguire@kumc.edu",{"name":27,"role":23,"phone":19,"phoneExt":19,"email":28},"Lucas Lemar","llemar@kumc.edu",[30,47],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"University of Kansas Strawberry Hill Campus","NOT_YET_RECRUITING","Kansas City","Kansas","66101","United States",{"type":38,"coordinates":39},"Point",[40,41],-94.62746,39.11417,{"lat":41,"lon":40},[44],{"name":45,"role":23,"phone":19,"phoneExt":19,"email":46},"Tyler Kjorvestad, MD","tkjorvestad@kumc.edu",{"facility":48,"status":49,"city":33,"state":34,"zip":50,"country":36,"cosmosGeoPoint":51,"geoPoint":53,"contacts":54},"University of Kansas Medical Center Emergency Department","RECRUITING","66160",{"type":38,"coordinates":52},[40,41],{"lat":41,"lon":40},[55],{"name":22,"role":23,"phone":56,"phoneExt":19,"email":25},"8048144509",{"type":58,"investigatorFullName":22,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"SPONSOR_INVESTIGATOR","Assistant Professor of Emergency Medicine","100522693",false,"NCT06085937","Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department","Feasibility and Safety of Single Dose Ketamine for Acutely Suicidal Patients in the Emergency Department","Inclusion Criteria:\n\n* Acutely Suicidality (\"yes\" answer to any of items 4 or 5 on C-SSRS \"Suicidal Ideation\" category)\n* Require inpatient stabilization for SI or actions based on clinical observation and interview\n* Are accepted for psychiatric stabilization at the University of Kansas Medical Center's Strawberry Hill campus\n* Have a Glasgow Coma Score (GCS) of 15\n* Age 18-65\n\nExclusion Criteria:\n\n* Current or past history of psychosis\n* Current or recent (past 4 weeks) symptoms of mania\u002Fhypomania as defined by Young Mania Rating Scale (YRMS) score of 12 or greater\n* History of ketamine use disorder\n* History of liver transplant\n* Pregnancy or breastfeeding\n* Imprisonment or inability to consent\n* Positive urine drug screen or serum alcohol level\n* Hypertension (SBP \\> 160 or DBP \\> 100 before administration of ketamine)\n* Hypotension (SBP \\\u003C 90)\n* Presence of acute medical condition requiring admission to medical service\n* Allergy, intolerance, or previous adverse reaction to ketamine\n* Patient has 8+ lifetime ketamine exposures\n* The treating physician determines that the patient is not a good candidate for the study (e.g. medical condition\u002Fprocedure, medication that would contradindicate ketamine treatment)","ALL","18 Years","65 Years",{"count":70,"type":71},50,"ESTIMATED","INTERVENTIONAL",[74],"PHASE1","There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.",[77,78,79],"Suicide","Suicidal Ideation","Depression","2026-04-12",{"date":82,"type":83},"2026-04-15","ACTUAL",{"date":85,"type":83},"2024-05-01",{"date":87,"type":71},"2027-04",{"name":22,"class":6},2]